Treatment Duration and Its Impact on the Number of Polymorphonuclear, Mononuclear and Neutrophil Lymphocyte Ratio as Indicators of Recovery Rate in Tuberculosis Patients
Downloads
The calculation of leukocyte types can be used to assess the level of infection or inflammation, particularly through the neutrophil-lymphocyte ratio (NLR). The NLR has been established as a useful biomarker for predicting bacteremia. Although differential leukocyte count and the neutrophil–lymphocyte ratio (NLR) have been widely proposed as indicators of infection and inflammation, their clinical interpretation remains unclear across disease states, particularly in tuberculosis. Current evidence is limited regarding how leukocyte profiles and NLR change during standard anti tuberculosis treatment (ATT), especially in the early and intermediate phases of therapy. Furthermore, it is not well established whether changes in leukocyte subtypes reflect treatment response or disease recovery in tuberculosis patients. Therefore, there is a need to quantify changes in leukocytes and NLR during TB treatment and to determine their potential role as readily accessible biomarkers for monitoring therapy outcomes. The goal of this study was to determine the effect of treatment duration on the number of polymorphonuclear cells, mononuclear cells, and the neutrophil-lymphocyte ratio as indicators of recovery in TB patients. This study employed a cross-sectional design with an analytical observational approach, involving 26 TB patients undergoing treatment for 1 to 6 months. The results showed the following average cell counts (per microliter) over the treatment period: basophils at 0.04, eosinophils at 0.30, neutrophils at 4.10, lymphocytes at 2.36, monocytes at 1.84, and a neutrophil-lymphocyte ratio of 0.53. One-way ANOVA analysis revealed a positive correlation between basophils, neutrophils, lymphocytes, monocytes, and the neutrophil-lymphocyte ratio with TB recovery. In conclusion, treatment of TB patients during the fourth to sixth month, or in the advanced phase of treatment showed differences in the number of polymorphonuclear cells, mononuclear cells and the NLR ratio compared to intensive phase treatment in TB patients at the Karang Taliwang and akranegara Health Centers.
Aini, A., Santoso, R.A., Pauzan, P., Halid, I., & Mentari, I. N. (2024). Variations in leukocyte counts of tuberculosis patients during the treatment period. Meditory, 12(2), 122-129.
Algifari, F., Purwitasari., & Muflihah, A. (2021). Scoping Review: Monocyte-Lymphocyte Ratio as a Supporting Tool for Establishing a Diagnosis in Tuberculosis Patients. Jurnal Integrasi Kesehatan & Sains, 3(2), 157-161. https://doi.org/10.29313/jiks.v3i2.7501
Anggreani, N., Wulan, I., Sudarsono, T. A., Wardani, D.P.K., & Rahaju, M. (2023). The Effect of Anti-Tuberculosis Drug (OAT) Administration on Platelet Count in Pulmonary TB Patients at BKPM Purwokerto. Jurnal Surya Medika 9(2), 281–90. https://doi.org/10.33084/jsm.v9i2.5727
Azmi, A. N., Hediningsih, Y., & Marfu’ati, N. (2023). A Comparison of Neutrophil Lymphocyte Ratio (NLR) Before and After Anti Tuberculosis Treatment Based on Age and Sex Characteristics. Mandala of Health, 16(2), 82-90. https://doi.org/10.20884/1.mandala.2023.16.2.8181
Babu, S. P., Narasimhan, P. B., & Babu, S. (2019). Eosinophil polymorphonuclear leukocytes in TB: what we know so far. Frontiers in immunology, 10, 2639. https://doi.org/10.3389/fimmu.2019.02639
Bloom, B.R. (2023). A Half-Century of Research on Tuberculosis: Successes and Challenges. The Journal of Experimental Medicine, 220 (9), 1–16. https://doi.org/10.1084/jem.20230859
Bohrer, A. C., Castro, E., Hu, Z., Queiroz, A. T., Tocheny, C. E., Assmann, M., ... & Mayer-Barber, K. D. (2021). Eosinophils are part of the granulocyte response in tuberculosis and promote host resistance in mice. Journal of Experimental Medicine, 218(10), e20210469. https://doi.org/10.1084/jem.20210469
Buonacera, A., Stancanelli, B., Colaci, M., & Malatino, L. (2022). Neutrophil to lymphocyte ratio: an emerging marker of the relationships between the immune system and diseases. International journal of molecular sciences, 23(7), 3636. https://doi.org/10.3390/ijms23073636
Coleman, M., Martinez, L., Theron, G., Wood, R., & Marais, B. (2022). Mycobacterium tuberculosis Transmission in High-Incidence Settings-New Paradigms and Insights. Pathogens (Basel, Switzerland), 11(11), 1228. https://doi.org/10.3390/pathogens11111228
Darwin, B., & Yolanda, M. B. (2023). Correlation of Leukocyte Number To Crp Levels in Tuberculosis Patients. Journal Health Applied Science and Technology, 1(1), 1-5. https://doi.org/10.52523/jhast.v1i1.1
Mancuso, G., Midiri, A., De Gaetano, S., Ponzo, E., & Biondo, C. (2023). Tackling drug-resistant tuberculosis: new challenges from the old pathogen Mycobacterium tuberculosis. Microorganisms, 11(9), 2277. https://doi.org/10.3390/microorganisms11092277
Kim, Y. S., Lee, J., Heo, S., Lee, J. H., & Jeong, D. W. (2021). Technology and safety evaluation of Bacillus coagulans exhibiting antimicrobial activity for starter development. LWT, 137, 110464. https://doi.org/10.1016/j.lwt.2020.110464
Kissling, M., Fritschi, N., Baumann, P., Buettcher, M., Bonhoeffer, J., Naranbhai, V., & Ritz, N. (2023). Monocyte, lymphocyte and neutrophil ratios–easy-to-use biomarkers for the diagnosis of pediatric tuberculosis. The Pediatric Infectious Disease Journal, 42(6), 520-527. https://doi.org/10.1097/INF.0000000000003901
Khalid, Z., Huan, M., Raza, M.S., Abbas, M., Naz, Z., Kombe, A.J.K., Zeng, W., He, H., Jin, T. (2022). Identification of Novel Therapeutic Candidates Against SARS-CoV-2 Infections: An Application of RNA Sequencing Toward mRNA Based Nanotherapeutics. Front Microbiol, 13, 901848. https://doi.org/10.3389/fmicb.2022.901848
Levy, Y., Derazne, E., Shilovsky, A., Kagansky, D., Derkath, A., Chepelev, V., Mazurez, E., Stambler, I., & Kagansky, N. (2023). Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio, Are They Markers of COVID-19 Severity or Old Age and Frailty ? A Comparison of Two Distinct Cohorts. Frontiers in Medicine, 10, 1–7. https//doi.org/10.3389/fmed.2023.1222692
Lubis, M.N.F. (2021). Analysis of Leukocyte Types and Counts in Tuberculosis Patients Undergoing Anti-Tuberculosis Drug Treatment for 2 Months at Medan's Special Pulmonary Hospital. Skripsi. Universitas Medan Area.
Nabilah, R. (2020). The Relationship Between Lymphocyte and Monocyte Levels and Severity in Extrapulmonary Tuberculosis Patients. Jurnal Ilmu Kedokteran dan Kesehatan, 7(3), 514-519. https://doi.org/10.33024/jikk.v7i3.2960
Omair, M., Baig, M. S., Farooqui, W. A., Kousar, S., Noori, M. Y., Zeehan, N., ... & Mehmood, M. (2024). Relationship of neutrophil lymphocyte ratio, monocyte lymphocyte ratio and neutrophil monocyte ratio with treatment response in pulmonary tuberculosis patients during intensive phase treatment. BMC infectious diseases, 24(1), 615. https://doi.org/10.1186/s12879-024-09454-2
Paton, N. I., Cousins, C., Suresh, C., Burhan, E., Chew, K. L., Dalay, V. B., ... & Crook, A. M. (2023). Treatment strategy for rifampin-susceptible tuberculosis. New England Journal of Medicine, 388(10), 873-887. https://doi.org/10.1056/nejmoa2212537
Permana, A. (2020). Description of Hemoglobin (Hb) and Leukocyte Levels in Pulmonary TB Patients with the Length of OAT (Anti-Tuberculosis Drug) Therapy at the Jakarta Cempaka Islamic Hospita. Anakes : Jurnal Ilmiah Analis Kesehatan, 6(2), 136–43. https://doi.org/10.37012/anakes.v6i2.364
Reta, B., Mohammed, A. E., Kiya, G. T., Adissu, W., & Shenkute, T. Y. (2023). Impact of anti-tuberculosis treatment on hematological parameters in newly diagnosed tuberculosis patients at Jimma town: a longitudinal prospective study. Annals of Medicine and Surgery, 85(8), 3887-3893. https://doi.org/10.1097/ms9.0000000000001084
Shima, Y., Masuda, T., Miwa, N., Kida, Y., Koketsu, R., Kamiryo, H., ... & Tada, K. (2024). Monocytes predict prognosis and successful treatment in older patients with miliary tuberculosis. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 35, 100437. https://doi.org/10.1016/j.jctube.2024.100437
Shojaan, H., Kalami, N., Alamdari, M. G., Alorizy, S. M. E., Ghaedi, A., Bazrgar, A., ... & Khanzadeh, S. (2023). Diagnostic value of the neutrophil lymphocyte ratio in discrimination between tuberculosis and bacterial community acquired pneumonia: A meta-analysis. Journal of clinical tuberculosis and other mycobacterial diseases, 33, 100395. https://doi.org/10.1016/j.jctube.2023.100395
Stefanescu, S., Cocoș, R., Turcu-Stiolica, A., Shelby, E. S., Matei, M., Subtirelu, M. S., ... & Pisoschi, C. G. (2021). Prediction of treatment outcome with inflammatory biomarkers after 2 months of therapy in pulmonary tuberculosis patients: Preliminary results. Pathogens, 10(7), 789. https://doi.org/10.3390/pathogens10070789
Sugiyono, S. (2023). Quantitative and Qualitative Research Methods, and R & D. Bandung: Alfabeta.
Yu, Y., Tan, D., Liao, C., Yang, P., Hu, Z., & Hao, L. (2022). Neutrophil-to-Lymphocyte Ratio as a Prognostic Predictor for Patients with Cancer Treated with Stereotactic Body Radiation Therapy: A Meta-Analysis. Molecular and Clinical Oncology, 16(5), 98. https://doi.org/10.3892/mco.2022.2531
Copyright (c) 2026 JURNAL INFO KESEHATAN
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright notice
Ownership of copyright
The copyright in this website and the material on this website (including without limitation the text, computer code, artwork, photographs, images, music, audio material, video material and audio-visual material on this website) is owned by JURNAL INFO KESEHATAN and its licensors.
Copyright license
JURNAL INFO KESEHATAN grants to you a worldwide non-exclusive royalty-free revocable license to:
- view this website and the material on this website on a computer or mobile device via a web browser;
- copy and store this website and the material on this website in your web browser cache memory; and
- print pages from this website for your use.
- All articles published by JURNAL INFO KESEHATAN are licensed under the Creative Commons Attribution 4.0 International License. This permits anyone to copy, redistribute, remix, transmit and adapt the work provided the original work and source is appropriately cited.
JURNAL INFO KESEHATAN does not grant you any other rights in relation to this website or the material on this website. In other words, all other rights are reserved.
For the avoidance of doubt, you must not adapt, edit, change, transform, publish, republish, distribute, redistribute, broadcast, rebroadcast or show or play in public this website or the material on this website (in any form or media) without appropriately and conspicuously citing the original work and source or JURNAL INFO KESEHATAN prior written permission.
Permissions
You may request permission to use the copyright materials on this website by writing to [email protected].
Enforcement of copyright
JURNAL INFO KESEHATAN takes the protection of its copyright very seriously.
If JURNAL INFO KESEHATAN discovers that you have used its copyright materials in contravention of the license above, JURNAL INFO KESEHATAN may bring legal proceedings against you seeking monetary damages and an injunction to stop you using those materials. You could also be ordered to pay legal costs.
If you become aware of any use of JURNAL INFO KESEHATAN copyright materials that contravenes or may contravene the license above, please report this by email to [email protected]
Infringing material
If you become aware of any material on the website that you believe infringes your or any other person's copyright, please report this by email to [email protected].
